Fresenius Kabi To Expand Sterile Mfg Operations
Fresenius Kabi, a Lake Zurich, Illinois-headquartered specialty and generic pharmaceuticals company and a subsidiary of Fresenius KGaA, a Bad Homburg, Germany-headquartered healthcare group, plans to invest $100 million to expand its sterile injectable manufacturing operations in Wilson County, North Carolina.
Fresenius Kabi’s plans in North Carolina include expansion of its current pharmaceutical production facility in Wilson and the construction of a new manufacturing facility, also in Wilson. Both sites will be dedicated to manufacturing products used in hospitals and clinics throughout the US and Canada. Fresenius Kabi has owned the Wilson site, which specializes in producing ready-to-administer syringes, since January 2016. The expansion will involve adding a variety of job functions, including production specialists, engineers, scientists, and managers.
Fresenius Kabi’s expansion in Wilson County will be facilitated, in part, by a Job Development Investment Grant (JDIG) by North Carolina’s Economic Investment Committee. Under the grant, the company agrees to create 445 jobs over five years. Using a formula that takes into account the new tax revenues generated by the new jobs, the JDIG agreement then authorizes the potential reimbursement to the company of up to $7.2 million, spread over 12 years.
Fresenius Kabi recently broke ground on a $250-million expansion at its pharmaceutical manufacturing site in Melrose Park, Illinois. In total, the company employs more than 3,000 people in the US and its US headquarters in Lake Zurich, Illinois.
Earlier this week, Fresenius Kabi also announced it is expanding its activities in Indonesia. PT Ethica Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceutical company, SOHO Global Health, have opened a new plant in Cikarang, Indonesia. The plant’s approximately 230 employees plan to produce a range of injectable drugs for therapeutic areas, including gynecology, anesthesia, and intensive care.